Induction chemotherapy of modified docetaxel, cisplatin, 5‐fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma

Abstract

BackgroundPrevious studies have investigated the value of induction chemotherapy (IC) in organ preservation strategies for head and neck cancers. This study evaluated the effectiveness of sequential IC with radiotherapy as a laryngeal preservation strategy for locally advanced hypopharyngeal carcinoma (LAHSCC).MethodsOne hundred and forty‐two consecutive patients with LAHSCC were retrospectively analyzed who received three IC regimens from 2015 to 2019.ResultsIn the TP (docetaxel plus cisplatin), TPF (TP plus 5‐fluorouracil), and TPX (TP plus capecitabine) IC groups, there were 51, 29, and 62 patients, respectively. The primary tumor objective response rates were 51%, 55.2%, and 71%, and the 3‐year survival rates with preserved larynx were 36.6%, 31.8%, and 51.2%, respectively (p = 0.03). There was no difference in overall survival and the adverse events were tolerable.ConclusionsThe TPX regimen displayed good efficacy and safety, indicating its potential as a therapeutic IC regimen for LAHSCC.

CT radiomics nomogram predicts pathological response after induced chemotherapy and overall survival in patients with advanced laryngeal cancer: A single-center retrospective study

“…Multivariate Cox analysis revealed that volume, N stage, and rad-score were statistically significant predictors of OS. Compared to PR patients, non-PR patients had significantly worse OS (p = 0.01), which is consistent with previous studies showing that non-PR patients had a poor prognosis for LC (26). The prognostic significance also differed between the PR and non-PR groups in both cohorts, consistent with the results of previous studies (27,28).…”

Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma

“…In previous study (Li et al, 2022), we have reported that modified TPF chemotherapy was an effective approach for laryngeal preservation in HPSCC. However, there were still 35%-45% of patients who showed no response after chemotherapy (Li et al, 2022).…”

“…In previous study (Li et al, 2022), we have reported that modified TPF chemotherapy was an effective approach for laryngeal preservation in HPSCC. However, there were still 35%-45% of patients who showed no response after chemotherapy (Li et al, 2022). In present study, we further identify the differentially expressed genes that are closely related to the TPF-chemotherapysensitivity (CS) in HPSCC by RNA sequencing.…”

“…Surgery combined with radiotherapy and chemotherapy is the main treatment method, among which cisplatin (DDP)-based chemotherapy is widely applied in HPSCC (Yu et al, 2014;Li et al, 2022). However, chemotherapeutic resistance resulted in treatment failure, including recurrence and distant metastasis in various human tumors (Yu et al, 2014).…”